ScholarMate
English简体中文繁體中文
客服熱線:400-1616-289
登入註冊
期刊論文

Clinical types of checkpoint inhibitor-related pneumonitis in lung cancer patients: a multicenter experience

Lin, Xinqing; Deng, Haiyi; Chen, Likun; Wu, Di; Chen, Xiaobo; Yang, Yilin; Chen, Tao; Xie, Xiaohong; Xie, Zhanhong; Liu, Ming; Ouyang, Ming; Qin, Yinyin; Li, Shiyue; Zhong, Nanshan; Gregg, Jeffrey P.; Horita, Nobuyuki; Song, Yong*; Zhou, Chengzhi*广州医学院; 南方医科大学; 中山大学; 1; y
Translational Lung Cancer Research2021-1DOI: 10.21037/tlcr-20-1258
12被引12閱讀
引用收藏
分享

摘要

Background: Checkpoint inhibitor-related pneumonitis (CIP) is not well classified according to clinical factors. We propose different clinical sub-types of CIP based on clinical factors and investigated the corresponding clinical features, treatments, and outcomes. @@@ Methods: We conducted a multicenter retrospective study of patients with lung cancer (including non-small cell lung cancer and small cell lung cancer) who developed CIP. The clinical characteristics, radiologic features, treatments, and outcomes of CIP were analyzed. @@@ Results: A total of 55 patients developed CIP and were classified into 3 groups as follows: 21 in the pure type (PT) group, 14 in the induced type (IT) group, and 20 in the mixed type (MT) group. The incidence of severe (grade 3-5) pneumonitis was significantly higher in the IT group than in the PT and MT groups (71.4% vs. 14.3% vs. 50.0%, P=0.002). Antiviral therapy was significantly more frequent in the IT group than in the PT and MT groups. Antibiotic therapy was administered in 23.8%, 71.4%, and 80.0% of patients with the PT, IT, and MT, respectively. The improvement time in the PT group was longer than that in the IT and MT groups (0.9 vs. 0.5 vs. 0.3 months, P=0.028). Patients with the PT had a better tumor response to immune checkpoint inhibitors (ICIs) than those with the other 2 types [overall response rate (ORR), 78% vs. 31% vs. 44%, P=0.027]. @@@ Conclusions: The clinical classification of CIP may favor strategies for treatments and predict the tumor response to ICIs.

學科與關鍵詞

關鍵詞
Immune checkpoint inhibitor (ICI)immune-related adverse eventscheckpoint inhibitor-related pneumonitis (CIP)lung cancerclinical types
相關
載入中…

文獻載入失敗,請重試

重試

發表資訊

論文狀態
公開發表
期刊
Translational Lung Cancer Research
發表日期
2021-01
卷期
第 10 卷, 第 1 期
頁碼
415-429
DOI
10.21037/tlcr-20-1258
期刊收錄
NSL
期刊等級
2区
成果收錄
SCIE
資助標註
Guangdong High-Level University Clinical Cultivation Project [2017-21020]; Guangzhou Science and Technology Program key projects [202008010006]; Wu Jieping Medical Foundation [20201101]

作者

  • L

    Lin, Xinqing (第一作者)

    1 · southern med univ · guangzhou med univ

  • D

    Deng, Haiyi

    1 · guangzhou med univ

查看全部 18 位作者收起作者
  • C

    Chen, Likun

    sun yat sen univ

  • W

    Wu, Di

    1 · 2

  • C

    Chen, Xiaobo

    1 · guangzhou med univ

  • Y

    Yang, Yilin

    1 · guangzhou med univ

  • C

    Chen, Tao

    1 · guangzhou med univ

  • X

    Xie, Xiaohong

    1 · guangzhou med univ

  • X

    Xie, Zhanhong

    1 · guangzhou med univ

  • L

    Liu, Ming

    1 · guangzhou med univ

  • O

    Ouyang, Ming

    1 · guangzhou med univ

  • Q

    Qin, Yinyin

    1 · guangzhou med univ

  • L

    Li, Shiyue

    1 · guangzhou med univ

  • Z

    Zhong, Nanshan

    1 · guangzhou med univ

  • G

    Gregg, Jeffrey P.

  • H

    Horita, Nobuyuki

  • S

    Song, Yong (通訊)

    1 · southern med univ

  • Z

    Zhou, Chengzhi (通訊)

    1 · guangzhou med univ

登入解鎖更多功能

  • 收藏這篇,隨時在「我的 · 收藏」找回
  • 認領你的成果,生成推廣素材
  • 關注作者獲取最新成果
  • 加入項目組、協同寫作
註冊 / 登入

產品服務

  • 科研之友
  • 創新城
  • 科創雲

服務支援

  • 幫助中心
  • 隱私政策
  • 服務條款

聯絡方式

線上客服:【】
客服熱線:400-1616-289
電子郵件:support@scholarmate.com

關注或下載科研之友

微信 QR Code
微信公眾號
客戶端下載 QR Code
下載客戶端
科研成果科研人員科研機構科研動態愛瑞思軟件

©2026 深圳市科研之友网络服务有限公司

公安備案圖示粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417